Accordingly, the dominant CD8+ TCR-Vβ+ expansions in T-LGLL patients were significantly more differentiated than the dominant CD8+ TCR-Vβ+ expansions in dasatinib-treated CML patients (Fig. 2C, left panel). This evidence concerns the gene CD8A and chronic myelogenous leukemia, BCR-ABL1 positive.